{"url_path":"/sec/tsha/8-k/2026-08-11/item-2-02","section_key":"item-2-02","section_title":"Item 2.02 Results of Operations and Financial Condition.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-08-11","source_url":"https://www.sec.gov/Archives/edgar/data/1806310/0001193125-26-344594-index.html","accession_number":"0001193125-26-344594","cik":"0001806310","ticker":"TSHA","issuer_name":"Taysha Gene Therapies, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1806310/0001193125-26-344594-index.html","primary_entity_key":"0001806310","primary_entity_name":"Taysha Gene Therapies, Inc."},"word_count":139,"has_tables":true,"body_markdown":"Item 2.02\n\nResults of Operations and Financial Condition.\n\nOn August 11, 2026, Taysha Gene Therapies, Inc. reported financial results for the quarter ended June 30, 2026, and recent business highlights. A copy of this press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference.\n\nThe information in this Item 2.02 of this Current Report on Form 8-K (including Exhibit 99.1) is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing."}